Replimune Anticipates Permanent J-code for TUDRIQEV by April 2027
Replimune Group, Inc. (REPL) has reached a significant milestone with the launch of TUDRIQEV, marking the first commercial product derived from its RPx platform. During the Q2 fiscal 2027 earnings call, management highlighted that the company is actively building launch metrics for the therapy. A key focus for the company's commercial strategy is securing a permanent J-code for TUDRIQEV, which is anticipated by April 2027. This administrative milestone is critical for streamlining reimbursement and increasing market accessibility for the product.
Tickers: $REPL
Topics: biotechnology commercial product launch earnings call